- The expanded partnership will allow Alnylam and
Medison to help accelerate access for patients in multiple regions
under one global alliance
- Medison, the creator and leader of the multi-regional
partnership category, will utilize its unique, unified
platform for efficient global commercialization of
Alnylam's innovative RNAi
technologies
ZUG, Switzerland, April 30, 2024 /PRNewswire/ --
Medison Pharma ("Medison"), a global pharma company
focused on providing access to highly innovative therapies for
patients in international markets, and Alnylam Pharmaceuticals,
Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company,
announced today a further expansion of their existing partnership
in Central & Eastern Europe
and Israel, to also include
selected markets in LATAM and APAC and additional international
markets.
Medison, the creator and leader of the multi-regional
partnership category, has established a unique, unified
commercialization platform in international markets, particularly
for the treatment of rare and severe diseases. Medison is the only
partner that focuses solely on the most innovative therapies.
Alnylam and Medison initially partnered in 2018. Ever since, the
partnership has expanded to additional regions and markets, to
ensure that Alnylam's commercial therapies, such as
ONPATTRO® (patisiran),
AMVUTTRA® (vutrisiran), GIVLAARI®
(givosiran), and OXLUMO® (lumasiran) are made
available across multiple international markets.
"We are delighted to extend yet again our existing partnership
with Medison, which will enable us to enhance our presence
and bring the benefits of Alnylam's innovative RNAi
therapeutics to patients in additional APAC and LATAM markets,"
said Norton Oliveira, Senior Vice-President and Head of
Partner and Emerging Markets at Alnylam. "Medison is at the
forefront of the global trend of consolidating international
markets under one alliance. Together, we'll provide faster access
to more patients around the world."
"The new category of the multi-regional partnerships that we
have been creating in the past few years continues to get traction
with the most innovative biotech companies," said Meir
Jakobsohn, Founder and Executive Chairman of Medison. "We are proud
of our longstanding partnership with Alnylam and will continue to
work together to bridge geographical gaps, ensuring that Alnylam's
life-saving therapies reach patients in need."
"Our unified commercial platform enables biotech companies to
transform numerous complex and fragmented markets and regions into
a unified territory, and we are proudly leading the trend and the
category," said Gil Gurfinkel, CEO
of Medison. "Our expanding partnership with Alnylam shows just how
our one-of-a-kind unified commercial platform, with single alliance
management across multiple markets and regions, is of great value
to leading biotech companies. This partnership will make Alnylam's
therapies available in additional international markets, offering
newfound hope for patients suffering from rare diseases."
About RNAi
RNAi (RNA interference) is a natural
cellular process of gene silencing that represents one of the most
promising and rapidly advancing frontiers in biology and drug
development today. Its discovery has been heralded as "a major
scientific breakthrough that happens once every decade or so," and
was recognized with the award of the 2006 Nobel Prize for
Physiology or Medicine. By harnessing the natural biological
process of RNAi occurring in our cells, a new class of medicines
known as RNAi therapeutics is now a reality. Small interfering RNA
(siRNA), the molecules that mediate RNAi and comprise Alnylam's
RNAi therapeutic platform, function upstream of today's medicines
by potently silencing messenger RNA (mRNA) – the genetic precursors
– that encode for disease-causing or disease pathway proteins, thus
preventing them from being made. This is a revolutionary approach
with the potential to transform the care of patients with genetic
and other diseases.
About Medison Pharma
Medison is a global pharma
company focused on providing access to highly innovative therapies
to patients in international markets, with presence in Central and
Eastern Europe, Canada, Latin
America, Asia Pacific,
Australia and Israel. Medison is the first to create an
international commercialization platform for highly innovative
therapies, helping to save and improve lives by making the best
available novel treatments accessible to patients in international
markets. Medison has a track record of multi-regional partnerships
with leading pharmaceutical and biotech companies seeking to expand
their global reach.
To learn more visit www.medisonpharma.com.
About Alnylam Pharmaceuticals
Alnylam
Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA
interference (RNAi) into a whole new class of innovative medicines
with the potential to transform the lives of people afflicted with
rare and prevalent diseases with unmet need. Based on Nobel
Prize-winning science, RNAi therapeutics represent a powerful,
clinically validated approach yielding transformative medicines.
Since its founding 20 years ago, Alnylam has led
the RNAi Revolution and continues to deliver on a bold
vision to turn scientific possibility into reality. Alnylam's
commercial RNAi therapeutic products are
ONPATTRO® (patisiran),
GIVLAARI® (givosiran),
OXLUMO® (lumasiran),
AMVUTTRA® (vutrisiran) and
Leqvio® (inclisiran), which is being developed and
commercialized by Alnylam's partner, Novartis. Alnylam has a
deep pipeline of investigational medicines, including multiple
product candidates that are in late-stage
development. Alnylam is executing on its "Alnylam
P5x25" strategy to deliver transformative medicines in
both rare and common diseases benefiting patients around the world
through sustainable innovation and exceptional financial
performance, resulting in a leading biotech profile. Alnylam
is headquartered in Cambridge, MA.
Logo:
https://mma.prnewswire.com/media/2391475/Medison_Pharma_and_Alnylam_Logo.jpg
Contacts:
Medison Pharma
Inbal Chen, Corporate Communications
T: +972-54-4400784
E: inbalc@medisonpharma.com
Alnylam Pharmaceuticals
Sara
Guzzone Fallon, Senior Director, Global Commercial
Communications
T: +1 631 335 1379
E: sfallon@alnylam.com
View original
content:https://www.prnewswire.co.uk/news-releases/medison-pharma-and-alnylam-pharmaceuticals-announce-expansion-of-their-multi-regional-partnership-in-europe-and-israel-to-commercialize-rnai-therapeutics-in-additional-latam-and-apac-markets-including-australia-302131429.html